NewsMarkets

Health

Moderna and Merck mRNA Vaccine Cuts Melanoma Recurrence Risk by 42 Percent

The personalized therapy, administered with Keytruda, significantly reduced recurrence or death, prompting AstraZeneca to consider entering the cancer vaccine market.

13 publishers · 17 articles · first seen 22 Oct 2026 · updated 11d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

13 publishers have covered this in 17 articles since 22 Oct 2026. Ars Technica published first, on 22 October at 22:12 UTC; BBC Health followed 9h 37m later. The most recent article, from Quartz, appeared on 27 October at 17:20 UTC.

Outlets reporting it: Ars Technica (major outlet), The New York Times (major outlet), WIRED (major outlet), Latest News from Science Magazine (major outlet), NPR Health (major outlet), Bloomberg.com (major outlet), BBC Health, STAT, New Scientist, MedPageToday.com - medical news for physicians, Quartz, MarketWatch and 1 more, all listed under Sources below.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

How it unfolded

Every source in the order it published.

  1. Ars TechnicaPersonalized mRNA cancer vaccine cut melanoma death, recurrence by 42%
  2. BBC HealthFirst personalised cancer vaccine cuts risk of disease returning in major trial
  3. The New York TimesMelanoma Vaccine Ushers in New Hope for Cancer Patients
  4. STATSTAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
  5. New ScientistPersonalised cancer vaccine expected to be approved next year
  6. MedPageToday.com - medical news for physiciansmRNA Melanoma Vaccine Cuts Risk of Recurrence or Death, Leaked Trial Data Show
  7. WIREDNew mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
  8. STATSTAT+: After a cancer vaccine’s first success, the race is on to expand the impact
  9. Latest News from Science MagazineMilestone cancer vaccine success leaves hard questions unanswered
  10. NPR HealthMerck's melanoma vaccine trial shows reduced recurrence or death from skin cancer
  11. Show 7 later sources
    1. QuartzModerna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42%
    2. Bloomberg.comHow Moderna and Merck’s mRNA Cancer Vaccine Emerged From Melanoma Research
    3. STATSTAT+: Five biotech updates to read after ESMO this weekend
    4. MarketWatchThe excitement around Moderna’s cancer vaccine is cooling. Here’s why.
    5. Inc.This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
    6. Bloomberg.comAstraZeneca May Enter Cancer Vaccine Development, CEO Says
    7. QuartzAstraZeneca might develop cancer vaccines, CEO tells analysts at oncology conference

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. AstraZeneca May Enter Cancer Vaccine Development, CEO Says Bloomberg.com ·
  2. How Moderna and Merck’s mRNA Cancer Vaccine Emerged From Melanoma Research Bloomberg.com ·
  3. Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer NPR Health ·
  4. Milestone cancer vaccine success leaves hard questions unanswered Latest News from Science Magazine ·
  5. New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent WIRED ·
  6. Melanoma Vaccine Ushers in New Hope for Cancer Patients The New York Times ·
Show 11 more sources
  1. Personalized mRNA cancer vaccine cut melanoma death, recurrence by 42% Ars Technica ·
  2. AstraZeneca might develop cancer vaccines, CEO tells analysts at oncology conference Quartz
  3. This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent Inc.
  4. The excitement around Moderna’s cancer vaccine is cooling. Here’s why. MarketWatch
  5. STAT+: Five biotech updates to read after ESMO this weekend STAT
  6. Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42% Quartz
  7. STAT+: After a cancer vaccine’s first success, the race is on to expand the impact STAT
  8. mRNA Melanoma Vaccine Cuts Risk of Recurrence or Death, Leaked Trial Data Show MedPageToday.com - medical news for physicians
  9. Personalised cancer vaccine expected to be approved next year New Scientist
  10. STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more STAT
  11. First personalised cancer vaccine cuts risk of disease returning in major trial BBC Health

In this story

  • Moderna
  • Merck
  • AstraZeneca
Embed this story

Paste this into any web page to show the live odds, with a link back here.